Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We encountered an oropharyngeal cancer patient with multiple bone metastases from prostate cancer who achieved a partial response to 3 cycles of combination chemotherapy including docetaxel, ifosfamide and cisplatin (DIP). A 72-year-old man was found to have advanced oropharyngeal cancer during hormonal treatment of bone metastases from prostate cancer. Combination chemotherapy was initiated with DIP. After chemotherapy, computed tomography revealed no residual tumor at the oropharyngeal region, but a small ulcer was seen at the base of the tongue by laryngopharyngoscopy. The patient obtained a partial response after 3 cycles of this regimen. During chemotherapy the patient could take oral meals because of no stomatitis. After chemotherapy the patient received radiation therapy (60 Gy/30 f). The oropharyngeal cancer disappeared completely after radiotherapy. It is suggested that combination chemotherapy with DIP is a potential new treatment modality for advanced head and neck cancer.
 ...
PMID:[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy]. 1567 84

Three regimes of combined treatment for intraoral and oropharyngeal cancer were compared. In group A, cisplatin 6 mg/m2 was given intravenously, daily; group B--40 mg/m2, weekly; group C--100 mg/m2, once in 3 weeks. All patients simultaneously received distant radiation therapy in a standard fractionated dose of 2 Gy per fraction, 5 times a week, up to TTD of 68-70 Gy. Among relatively frequent side-effects were granulocytopenia, asthenia and stomatitis. Overall immediate effectiveness was: group A--100%, group B--96% and group C--100%. The rates of complete tumor resorption were: group A--27.3%, group B--19.2% and group C--16.7%.
 ...
PMID:[Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer]. 1815 24